Monoclonal Antibodies Against Pancreatic Cancer
Author Information
Author(s): A.G. Grant, P.M. Harris, E. Heyderman, S.E. Larkin, B. Pym, J. Hermon-Taylor
Primary Institution: St. George's Hospital Medical School
Hypothesis
Can different immunisation regimes generate spleen cells that produce monoclonal antibodies reactive against human pancreatic exocrine cancer?
Conclusion
The study successfully generated monoclonal antibodies that may be useful for detecting pancreatic tumors.
Supporting Evidence
- Immunised spleen cells generated 13% of hybridoma supernatants that showed selectivity for pancreatic cancer cells.
- Monoclonal antibody DD9E7 identified an antigen expressed on 12 out of 14 pancreatic adenocarcinomas.
- Antibodies produced showed strong staining of malignant luminal membranes and cytoplasm.
Takeaway
Scientists tried different ways to make special antibodies that can find pancreatic cancer cells, and they found one that works really well.
Methodology
The study involved immunising mice with pancreatic cancer cells, fusing their spleen cells with a myeloma line, and screening for antibodies that bind to pancreatic cancer cells.
Limitations
The study's methods may not be applicable to all types of pancreatic cancer due to the specificity of the generated antibodies.
Participant Demographics
Outbred congenitally athymic 'nude' mice and hairy litter mates were used in the study.
Want to read the original?
Access the complete publication on the publisher's website